| Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption Y Shitara, K Maeda, K Ikejiri, K Yoshida, T Horie, Y Sugiyama Biopharmaceutics & drug disposition 34 (1), 45-78, 2013 | 433 | 2013 |
| Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective M Shebley, P Sandhu, A Emami Riedmaier, M Jamei, R Narayanan, ... Clinical Pharmacology & Therapeutics 104 (1), 88-110, 2018 | 296 | 2018 |
| Identification of the rate‐determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study K Maeda, Y Ikeda, T Fujita, K Yoshida, Y Azuma, Y Haruyama, N Yamane, ... Clinical Pharmacology & Therapeutics 90 (4), 575-581, 2011 | 216 | 2011 |
| Clinical probes and endogenous biomarkers as substrates for transporter drug‐drug interaction evaluation: perspectives from the international transporter consortium X Chu, M Liao, H Shen, K Yoshida, AA Zur, V Arya, A Galetin, ... Clinical Pharmacology & Therapeutics 104 (5), 836-864, 2018 | 160 | 2018 |
| Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies K Yoshida, K Maeda, Y Sugiyama Clinical Pharmacology & Therapeutics 91 (6), 1053-1064, 2012 | 157 | 2012 |
| Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms K Yoshida, K Maeda, Y Sugiyama Annual review of pharmacology and toxicology 53, 581-612, 2013 | 138 | 2013 |
| Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes E Kimoto, K Yoshida, LM Balogh, Y Bi, K Maeda, A El-Kattan, Y Sugiyama, ... Molecular pharmaceutics 9 (12), 3535-3542, 2012 | 115 | 2012 |
| Quantitative analyses of hepatic OATP‐mediated interactions between statins and inhibitors using PBPK modeling with a parameter optimization method T Yoshikado, K Yoshida, N Kotani, T Nakada, R Asaumi, K Toshimoto, ... Clinical Pharmacology & Therapeutics 100 (5), 513-523, 2016 | 97 | 2016 |
| Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1 J Vaidyanathan, K Yoshida, V Arya, L Zhang The Journal of Clinical Pharmacology 56, S59-S72, 2016 | 96 | 2016 |
| Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3 CH Hsueh, K Yoshida, P Zhao, TW Meyer, L Zhang, SM Huang, ... Molecular pharmaceutics 13 (9), 3130-3140, 2016 | 85 | 2016 |
| Microdosing and other phase 0 clinical trials: facilitating translation in drug development T Burt, K Yoshida, G Lappin, L Vuong, C John, SN De Wildt, Y Sugiyama, ... Clinical and translational science 9 (2), 74, 2016 | 84 | 2016 |
| Effect of chronic kidney disease on nonrenal elimination pathways: a systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP ML Tan, K Yoshida, P Zhao, L Zhang, TD Nolin, M Piquette‐Miller, ... Clinical Pharmacology & Therapeutics 103 (5), 854-867, 2018 | 79 | 2018 |
| Clinical drug–drug interaction evaluations to inform drug use and enable drug access D Rekić, KS Reynolds, P Zhao, L Zhang, K Yoshida, M Sachar, MP Miller, ... Journal of pharmaceutical sciences 106 (9), 2214-2218, 2017 | 73 | 2017 |
| In vitro–in vivo extrapolation of metabolism-and transporter-mediated drug–drug interactions—overview of basic prediction methods K Yoshida, P Zhao, L Zhang, DR Abernethy, D Rekić, KS Reynolds, ... Journal of pharmaceutical sciences 106 (9), 2209-2213, 2017 | 67 | 2017 |
| Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology K Yoshida, N Budha, JY Jin Clinical Pharmacology & Therapeutics 101 (5), 597-602, 2017 | 66 | 2017 |
| Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5 K Yoshida, B Sun, L Zhang, P Zhao, DR Abernethy, TD Nolin, ... Clinical Pharmacology & Therapeutics 100 (1), 75-87, 2016 | 62 | 2016 |
| Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI NS Jones, K Yoshida, L Salphati, JR Kenny, MR Durk, LW Chinn Clinical Pharmacology & Therapeutics 107 (1), 269-277, 2020 | 55 | 2020 |
| Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects H Kusuhara, M Miura, N Yasui-Furukori, K Yoshida, Y Akamine, ... Drug Metabolism and Disposition 41 (1), 206-213, 2013 | 48 | 2013 |
| Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease K Yoshida, A Moein, T Bittner, S Ostrowitzki, H Lin, L Honigberg, JY Jin, ... Alzheimer's research & therapy 12, 1-12, 2020 | 42 | 2020 |
| Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models K Yoshida, K Maeda, H Kusuhara, A Konagaya BMC systems biology 7, 1-11, 2013 | 33 | 2013 |
